Skip to main content
SRPT logo

SRPT · Sarepta Therapeutics, Inc.

Track SRPT — free
$18.10 -0.32 (-1.74%) At close · Aug 14
Market Cap
$1.91B
Shares
105.63M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Douglas S. Ingram $7,840,666
Louise Rodino-Klapac $4,456,270
Ian M. Estepan $4,444,392
Cristin L. Rothfuss $4,233,623
Ryan H. Wong $3,211,867
Dallan Murray $2,742,790
Fiscal 2024
Executive Total
Ian M. Estepan $2,752,522
Louise Rodino-Klapac $2,737,283
Dallan Murray $2,666,323
Ryan E. Brown $2,611,129
Bilal Arif $2,539,138
Douglas S. Ingram $1,978,086
Ryan H. Wong
Cristin L. Rothfuss
Fiscal 2023
Executive Total
Louise Rodino-Klapac $3,718,991
Ian M. Estepan $3,705,626
Ryan E. Brown $3,578,331
Bilal Arif $3,520,586
Douglas S. Ingram $1,661,338
General Counsel
Dallan Murray
Ryan H. Wong
Fiscal 2022
Executive Total
Douglas S. Ingram $124,938,694
Louise Rodino-Klapac $3,941,777
Ian M. Estepan $3,823,989
Ryan E. Brown $3,729,818
Bilal Arif
Dallan Murray
Fiscal 2021
Executive Total
Louise Rodino-Klapac $8,515,533
Ian M. Estepan $5,127,595
Ryan Brown $5,104,290
Chief General Counsel $5,104,200
William F. Ciambrone $5,046,221
Douglas S. Ingram $1,546,324
Bilal Arif
Fiscal 2020
Executive Total
Gilmore O’Neill $7,576,022
Louise Rodino-Klapac $7,269,883
David Tyronne Howton $5,703,078
Ian M. Estepan $5,177,795
Sandesh Mahatme $3,364,021
Douglas S. Ingram $1,291,947
Joseph Bratica $911,887
William F. Ciambrone $680,419
Ryan Brown
Fiscal 2019
Executive Total
Sandesh Mahatme $5,161,209
William F. Ciambrone $4,345,194
David Tyronne Howton $4,196,622
Gilmore O’Neill $3,790,049
Douglas Ingram $1,387,072
Douglas S. Ingram $1,387,072
Joseph Bratica
Ian M. Estepan
Louise Rodino-Klapac
General Counsel
Fiscal 2018
Executive Total
Gilmore O’Neill $5,168,110
Sandesh Mahatme $4,219,084
David Tyronne Howton $3,129,375
Douglas S. Ingram $1,433,872
Douglas Ingram $1,433,872
Corporate Controller
William F. Ciambrone
Ian M. Estepan
Louise Rodino-Klapac
Fiscal 2017
Executive Total
Douglas Ingram $56,866,241
Sandesh Mahatme $2,200,133
David Tyronne Howton $1,823,528
Gilmore O’Neill
William F. Ciambrone

Executive changes

Person Change Filed
Michael Severino, M.D. Appointed 2026-07-27
Michael Severino, M.D. Appointed 2026-07-27
Deirdre Connelly Appointed 2026-06-04
Michael Chambers Appointed 2026-06-04
Kathryn J. Boor, Ph.D. Appointed 2026-06-04
Hans Wigzell, M.D., Ph.D. Appointed 2026-06-04
Douglas S. Ingram Appointed 2026-06-04
Bilal Arif Terminated 2025-08-13
Louise Rodino-Klapac Appointed 2025-07-16
Ryan Wong Appointed 2025-07-16
Ian Estepan Appointed 2025-07-16
Claude Nicaise, M.D. Appointed 2025-06-06
Stephen L. Mayo, Ph.D. Appointed 2025-06-06
M. Kathleen Behrens, Ph.D. Appointed 2025-06-06
Richard J. Barry Appointed 2025-06-06
Deirdre Connelly Appointed 2024-09-16
Bilal Arif Appointed 2022-11-02
William F. Ciambrone Resigned 2022-11-02
Hans Wigzell, M.D., Ph.D. Appointed 2022-06-03
Michael Chambers Appointed 2022-06-03
Douglas S. Ingram Appointed 2022-06-03
Kathryn Boor, Ph.D. Appointed 2022-06-03
Key facts CIK 873303 CUSIP 803607100 13F (30d) 333 filings 300 filers Visit website Investor relations